Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Clinical Measurement Ontology Resource Report Resource Website |
Clinical Measurement Ontology (RRID:SCR_003291) | CMO | ontology, data or information resource, controlled vocabulary | An ontology designed to be used to standardize morphological and physiological measurement records generated from clinical and model organism research and health programs. | obo, phenotype, clinical, measurement, morphology, physiology |
is listed by: SourceForge is listed by: BioPortal is listed by: OBO has parent organization: Medical College of Wisconsin; Wisconsin; USA |
PMID:22654893 | Free, Freely available | nlx_157364 | http://sourceforge.net/projects/phenoonto/ ftp://rgd.mcw.edu/pub/ontology/clinical_measurement/clinical_measurement.obo |
SCR_003291 | 2026-02-16 09:46:11 | 0 | ||||||
|
Measurement Method Ontology Resource Report Resource Website |
Measurement Method Ontology (RRID:SCR_003373) | MMO | ontology, data or information resource, controlled vocabulary | An ontology designed to represent the variety of methods used to make qualitative and quantitative clinical and phenotype measurements both in the clinic and with model organisms. | obo, phenotype, clinical |
is listed by: SourceForge is listed by: BioPortal is listed by: OBO |
PMID:22654893 | Free, Available for download, Freely available | nlx_157468 | http://sourceforge.net/projects/phenoonto/ ftp://rgd.mcw.edu/pub/ontology/measurement_method/measurement_method.obo |
SCR_003373 | 2026-02-16 09:46:00 | 0 | ||||||
|
Malaria Ontology Resource Report Resource Website |
Malaria Ontology (RRID:SCR_003369) | IDOMAL | ontology, data or information resource, controlled vocabulary | An application ontology to cover all aspects of malaria (clinical, epidemiological, biological, etc) as well as the intervention attempts to control it, extending the infectious disease ontology (IDO). | obo, health, pathological, clinical, epidemiological, biological, intervention |
is listed by: BioPortal is listed by: OBO has parent organization: AnoBase: An Anopheles database |
Malaria | Free, Available for download, Freely available | nlx_157464 | http://purl.obolibrary.org/obo/idomal.obo http://anobase.vectorbase.org/idomal/IDOMAL.obo |
SCR_003369 | 2026-02-16 09:46:04 | 0 | ||||||
|
miniTUBA Resource Report Resource Website |
miniTUBA (RRID:SCR_003447) | miniTUBA | production service resource, service resource, storage service resource, analysis service resource | miniTUBA is a web-based modeling system that allows clinical and biomedical researchers to perform complex medical/clinical inference and prediction using dynamic Bayesian network analysis with temporal datasets. The software allows users to choose different analysis parameters (e.g. Markov lags and prior topology), and continuously update their data and refine their results. miniTUBA can make temporal predictions to suggest interventions based on an automated learning process pipeline using all data provided. Preliminary tests using synthetic data and laboratory research data indicate that miniTUBA accurately identifies regulatory network structures from temporal data. miniTUBA represents in a network view possible influences that occur between time varying variables in your dataset. For these networks of influence, miniTUBA predicts time courses of disease progression or response to therapies. minTUBA offers a probabilistic framework that is suitable for medical inference in datasets that are noisy. It conducts simulations and learning processes for predictive outcomes. The DBN analysis conducted by miniTUBA describes from variables that you specify how multiple measures at different time points in various variables influence each other. The DBN analysis then finds the probability of the model that best fits the data. A DBN analysis runs every combination of all the data; it examines a large space of possible relationships between variables, including linear, non-linear, and multi-state relationships; and it creates chains of causation, suggesting a sequence of events required to produce a particular outcome. Such chains of causation networks - are difficult to extract using other machine learning techniques. DBN then scores the resulting networks and ranks them in terms of how much structured information they contain compared to all possible models of the data. Models that fit well have higher scores. Output of a miniTUBA analysis provides the ten top-scoring networks of interacting influences that may be predictive of both disease progression and the impact of clinical interventions and probability tables for interpreting results. The DBN analysis that miniTUBA provides is especially good for biomedical experiments or clinical studies in which you collect data different time intervals. Applications of miniTUBA to biomedical problems include analyses of biomarkers and clinical datasets and other cases described on the miniTUBA website. To run a DBN with miniTUBA, you can set a number of parameters and constrain results by modifying structural priors (i.e. forcing or forbidding certain connections so that direction of influence reflects actual biological relationships). You can specify how to group variables into bins for analysis (called discretizing) and set the DBN execution time. You can also set and re-set the time lag to use in the analysis between the start of an event and the observation of its effect, and you can select to analyze only particular subsets of variables. | analysis, analyze, bayesian, causation, clinical, linear, medical, structure, temporal, network analysis, network, molecule, information refining, gene expression regulation, bioinformatics, statistical package, interaction network, prediction, pathway, inference, biomedical, intervention |
is listed by: Biositemaps has parent organization: National Center for Integrative Biomedical Informatics has parent organization: University of Michigan; Ann Arbor; USA |
Society of University Surgeons Foundation ; NIDA U54DA021519; NIAID 1R21AI057875-01; NIGMS K08 GM074678-01A1 |
PMID:17644819 | Free, Freely available | nif-0000-33272 | SCR_003447 | miniTUBA - Medical Inference by Network Integration of Temporal Data using Bayesian Analysis tool, Medical Inference by Network Integration of Temporal Data using Bayesian Analysis tool, Medical Inference by Network Integration of Temporal Data using Bayesian Analysis tool (miniTUBA), The Medical Inference by Network Integration of Temporal Data using Bayesian Analysis tool | 2026-02-16 09:46:08 | 0 | |||||
|
NCI Thesaurus Resource Report Resource Website 1+ mentions |
NCI Thesaurus (RRID:SCR_003563) | NCIt | ontology, data or information resource, controlled vocabulary | A reference terminology and core biomedical ontology for NCI that covers approximately 100,000 key biomedical concepts with terms, codes, definitions, and more than 200,000 inter-concept relationships. It is the reference terminology for NCI, NCI Metathesaurus and NCI informatics infrastructure covering vocabulary for clinical care, translational and basic research, and public information and administrative activities. It includes broad coverage of the cancer domain, including cancer related diseases, findings and abnormalities; anatomy; agents, drugs and chemicals; genes and gene products and so on. In certain areas, like cancer diseases and combination chemotherapies, it provides the most granular and consistent terminology available. It combines terminology from numerous cancer research related domains, and provides a way to integrate or link these kinds of information together through semantic relationships. NCIt features: * Stable, unique codes for biomedical concepts; * Preferred terms, synonyms, definitions, research codes, external source codes, and other information; * Links to NCI Metathesaurus and other information sources; * Over 200,000 cross-links between concepts, providing formal logic-based definition of many concepts; * Extensive content integrated from NCI and other partners, much available as separate NCIt subsets * Updated frequently by a team of subject matter experts. NCIt is a widely recognized standard for biomedical coding and reference, used by a broad variety of public and private partners both nationally and internationally including the Clinical Data Interchange Standards Consortium Terminology (CDISC), the U.S. Food and Drug Administration (FDA), the Federal Medication Terminologies (FMT), and the National Council for Prescription Drug Programs (NCPDP). | thesaurus, clinical, treatment, prevention, biomedical, owl, health, drug, chemotherapy |
is listed by: OBO is listed by: BioPortal is related to: NCI Metathesaurus is related to: OnEx - Ontology Evolution Explorer has parent organization: National Cancer Institute |
Cancer | See license, http://evs.nci.nih.gov/ftp1/NCI_Thesaurus/NCI_THESAURUS_license.txt | nlx_157698 | ftp://ftp1.nci.nih.gov/pub/cacore/EVS/ https://cabig.nci.nih.gov/concepts/EVS/ https://wiki.nci.nih.gov/display/EVS/NCI+Thesaurus+%28NCIt%29 http://nciterms.nci.nih.gov http://purl.bioontology.org/ontology/NCIT |
http://ncicb.nci.nih.gov/core/EVS | SCR_003563 | ncithesaurus | 2026-02-16 09:46:08 | 9 | ||||
|
California Integrated Data Exchange Resource Report Resource Website |
California Integrated Data Exchange (RRID:SCR_003747) | Cal INDEX | data or information resource, organization portal, consortium, portal | A three-year consortium that brings together insurers and health care providers to share information from approximately 9 million patients, with a goal that insights from the data will bring down healthcare costs and improve outcomes. It aims to be one of the largest health information exchanges in the country, with the goal of better connecting the vast, often disparate healthcare landscape across California. The database that will house patient data will be overseen by Orion Health, an independent eHealth software company. The information will only be used for clinical purposes. Academic research institutions can apply to use the Cal INDEX de-identified data for research to benefit the public good, such as population health initiatives. Cal INDEX has five main goals: * Improve the quality of care by providing clinicians with a unified statewide source of integrated patient information * Provide patients with a seamless transition between health plans or across various healthcare professionals and hospitals * Improve efficiency and reduce the cost of healthcare * Encourage healthcare technology innovation * Improve public health by providing de-identified data for medical research. Cal INDEX plans to launch at the end of 2014 with approximately 9 million health information records from combined members of Dignity Health and Blue Shield of California and Anthem Blue Cross. Cal INDEX is open to any health data contributor. Cal INDEX will establish a bi-directional data interface with providers to exchange data with EMRs and other hospital and office-based systems. | healthcare, data sharing, tool development, consortium, health information exchange, health information, health, california, clinical, electronic patient record, database, de-identified | is listed by: Consortia-pedia | Blue Shield of California ; Anthem Blue Cross |
nlx_157980 | SCR_003747 | 2026-02-16 09:46:14 | 0 | ||||||||
|
Advanced Immunization Technologies Resource Report Resource Website 1+ mentions |
Advanced Immunization Technologies (RRID:SCR_003741) | ADITEC | data or information resource, organization portal, consortium, portal | A consortium that aims to accelerate the development of immunization technologies for the next generation of human vaccines. The goals are to characterize the mode of action and conduct comparative effectiveness studies of: adjuvants, vectors, formulations, delivery devices, routes of immunization, homologous and heterologous primeboost schedules, on vaccine efficacy. As part of these clinical trials, the consortium will also investigate the impact of host factors such as age, gender, genetics and pathologies. The consortium hopes to use insights gained from their projects to advance the development of next-generation vaccines, using tools such as standardized animal models to select promising immunization technologies. The intended outcome of this partnership is to improve the vaccine development process by advancing: basic research, new technology development, and clinical trial methods. Scientific objectives: # Development of adjuvants, vectors, formulations, and delivery devices # Selection of candidates, routes of immunization, and prime-boost combinations in animal models # Assessment of the impact of host factors in response to vaccination # Development of concepts and tools from human immunization # Development of concepts and tools to address regulatory and ethical issues posed by novel immunization technologies # Creation of an internationally recognized training program for translational immunology and vaccinology. Data is shared across the research partners within and between the different workstreams. Additionally, the consortium has plans to create a clinical database that combines phenotypic and clinical information to study the immune response to influenza vaccination at a population level, in an effort to advance studies into the effects of genetic background, gender, and disease on vaccine response. | drug, consortium, drug development, biomarker, vaccine, immunization, vaccine technology, adjuvant, vector, route, device, prime-boost, host factor, system biology, technology, animal model, human immunology, immunology, phenotype, clinical, clinical trial, public health | is listed by: Consortia-pedia | European Union FP7 280873 | nlx_157968 | SCR_003741 | Advanced Immunization Technologies (ADITEC) | 2026-02-16 09:46:11 | 8 | |||||||
|
ABIRISK Resource Report Resource Website 10+ mentions |
ABIRISK (RRID:SCR_003740) | ABIRISK | data or information resource, organization portal, consortium, portal | A consortium that seeks to provide an integrated approach to anti-drug immunization by evaluating immunogenicity in hemophilia A, multiple sclerosis, and inflammatory diseases, and exploring new tools for protein drug immunogenicity. The data collected will be pooled in a single immunogenicity databank and will be standardized and used to develop models of anti-drug antibodies. By examining the correlation between patient and clinical factors and the incidence of immunogenicity, it hopes to reduce the regulatory and resource burdens of immunogenicity testing. The objectives of the consortium are: # Access to large cohorts of patients treated with marketed biopharmaceutical products # Complementary expertise for anti-drug antibodies (ADA) assays; standardization and characterization of ADA # Novel integrated approaches to characterize anti-drug lymphocyte responses # Development and validation of innovative prediction tools # Collection and integration of immunogenicity-related data and clinical relevance of ADA ABIRISK is grouped into five working projects, which communicate with one another and provide each other with results and data for analysis. The five working projects are: ADA assay development and validation and cohort management; cellular characterization and mechanisms of the AD immune response; evaluation and development of technologies for predicting immunogenicity; establishment of database, data analyses and integration; and project management and communication. | drug, consortium, drug development, biomarker, pharmacogenomics, biopharmaceutical product, immune response, immunogenicity, data sharing, immune system, biopharmaceutical, clinical |
uses: eTRIKS is listed by: Consortia-pedia |
Innovative Medicines Initiative 115303 | nlx_157967 | SCR_003740 | Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk, ABIRISK Project | 2026-02-16 09:46:06 | 16 | |||||||
|
EU-AIMS Resource Report Resource Website 1+ mentions |
EU-AIMS (RRID:SCR_003861) | EU-AIMS | data or information resource, organization portal, consortium, portal | Consortium aiming to generate tools that will enhance understanding of autism spectrum disorders (ASD) and pave the way for the development of new, safe and effective treatments for use in both children and adults. For example, the team will gather samples from people bearing certain mutations associated with ASD; this will pave the way for the generation of cell lines that can be used to test treatments. Elsewhere, the researchers will advance the use of brain scans as a tool to boost ASD drug discovery and also identify which people with ASD might respond best to a given drug. The project will also create a pan-European network of clinical sites. As well as making it easier to run clinical trials, this network will create an interactive platform for those with ASD and professionals. By the end of the 5 year project they expect to provide novel validated cellular assays, animal models, new fMRI methods with dedicated analysis techniques, new PET radioligands, as well as new genetic and proteomic biomarkers for patient-segmentation or individual response prediction. They will provide a research network that can rapidly test new treatments in man. These tools should provide their EFPIA partners with an added competitive advantage in developing new drugs for ASD. | basic science, tool development, child, adult human, young human, treatment, diagnose, symptom, clinical, cell line, drug, drug discovery, neuroimaging, mutation, clinical trial, medicine |
is listed by: Consortia-pedia is related to: Roche is related to: Janssen Research and Development is related to: Pfizer Animal Genetics is related to: King's College London; London; United Kingdom is related to: Birkbeck University of London; London; United Kingdom is related to: Central Institute of Mental Health; Mannheim; Germany is related to: CEA; Gif sur Yvette; France is related to: European Molecular Biology Laboratory is related to: University College London; London; United Kingdom is related to: Pasteur Institute is related to: Karolinska Institute; Stockholm; Sweden is related to: Max-Planck-Gesellschaft is related to: Biomedical University Campus of Rome; Rome; Italy is related to: University of Basel; Basel; Switzerland is related to: Ulm University; Baden-Wurttemberg; Germany is related to: University of Cambridge; Cambridge; United Kingdom is related to: Autism Speaks is related to: GABO:mi is related to: deCODE genetics is related to: Noldus has parent organization: Roche |
Innovative Medicines Initiative ; EFPIA |
nlx_158184 | SCR_003861 | European Autism Interventions - A Multicentre Study for Developing New Medications, European Autism Interventions | 2026-02-16 09:46:15 | 2 | |||||||
|
EARIP Resource Report Resource Website |
EARIP (RRID:SCR_003854) | EARIP | data or information resource, organization portal, consortium, portal | Consortium that convenes asthma experts from across Europe to define research gaps to reduce the impact of asthma. The project activities range from basic cell science research, to assessing and improving European healthcare systems. Their activities include workshops, prioritization exercises, consensus strategies, and the development and publication of a set of recommendations about what's needed to reduce asthma deaths and hospitalizations. The eventual goal is to have a comprehensive R&D roadmap for asthma. EARIP will target a number of asthma research areas to ensure a comprehensive overview of all current research strategies from across Europe is included in the project road map. These include: * Research into biological targets, aiming to discover new targets and better define the role of existing biological targets * Identify new systems, models and tools for phenotypic stratification * Develop better and more efficient healthcare systems across Europe * Define and develop new diagnostic tools * Assess and improve patient self-management systems and provide suggestions for how these can be developed * Identify how to establish a European Innovation Partnership (EIP) for the management of asthma * Establish a European research network of clinical asthma research facilities | biomarker, biological target, tool development, clinical, basic research |
is listed by: Consortia-pedia is related to: Imperial College London; London; United Kingdom is related to: Karolinska Institute; Stockholm; Sweden is related to: European Federation of Allergy and Airways Diseases Patients Associations is related to: European Lung Foundation is related to: University of Athens; Athens; Greece is related to: University of Southampton; Southampton; United Kingdom is related to: Swiss Institute of Allergy and Asthma Research is related to: University of Lodz; Lodz; Poland has parent organization: Asthma UK |
European Union FP7-Health Programme 602077 | nlx_158171 | SCR_003854 | European Asthma Research and Innovation Partnership, European Asthma Research and Innovation Partnership (EARIP) | 2026-02-16 09:46:08 | 0 | |||||||
|
OncoTrack Resource Report Resource Website 1+ mentions |
OncoTrack (RRID:SCR_003767) | OncoTrack | data or information resource, organization portal, consortium, portal | An international consortium to develop and assess novel approaches to identify and characterize biological markers for colon cancer that will deepen the understanding of the variable make-up of tumors and how this affects the way patients respond to treatment. They will use cutting edge laboratory-based genome sequencing techniques coupled to novel computer modelling approaches to study both the biological heterogeneity of colon cancers (i.e. patient to patient variability) as well as tumor variation within the patient for example, by comparing primary tumors with metastases. This five year project brings together top scientists from European academic institutions offering a wide range of expertise, and partners them with pharmaceutical companies. The project is based on the premise that this genetic and epigenetic information, combined with a description of the molecular pathology of the tumor, will allow OncoTrack to generate a more accurate in-silico model of the cancer cell. This will facilitate the identification of predictive markers that can be used to guide the optimal therapy strategy at the level of the individual patient - and will also provide on-going prognostic guidance for the clinician. This project will not only advance understanding of the fundamental biology of colon cancers but will provide the means and approach for the identification of previously undetected biomarkers not only in the cancer under study, but potentially also in other solid cancers and, in doing so, open the door for personalized management of the oncology patient. | oncology, biomarker, diagnosis, basic science, genome sequencing, computer modelling, genetic, epigenetic, pathology, model, cancer cell, colon, cancer, treatment, genomics, clinical, systems biology, in-silico model, patient variability, tumor variability |
uses: GenomeWeb uses: eTRIKS is listed by: Consortia-pedia is related to: Roche is related to: Janssen Research and Development is related to: Merck is related to: Pfizer Animal Genetics is related to: Charite - Universitatsmedizin Berlin; Berlin; Germany is related to: Max Planck Institute for Molecular Genetics; Berlin; Germany is related to: Medical University of Graz; Graz; Austria is related to: Paris-Sud University; Paris; France is related to: Dresden University of Technology; Saxony; Germany is related to: University College London; London; United Kingdom is related to: Uppsala University; Uppsala; Sweden is related to: Stockholm University; Stockholm; Sweden is related to: Vall d'Hebron Institute of Oncology; Barcelona; Spain is related to: Alacris Theranostics is related to: Experimental Pharmacology and Oncology Berlin-Buch is related to: GABO:mi is related to: International Prevention Research Institute has parent organization: Max Planck Institute for Molecular Genetics; Berlin; Germany |
Innovative Medicines Initiative ; EFPIA |
nlx_158037 | SCR_003767 | OncoTrack - Methods for systematic next generation oncology biomarker development, Onco Track | 2026-02-16 09:46:14 | 9 | |||||||
|
Polycystic Kidney Disease Outcomes Consortium Resource Report Resource Website |
Polycystic Kidney Disease Outcomes Consortium (RRID:SCR_003674) | PKDOC | data or information resource, organization portal, consortium, portal | Consortium to develop evidence supporting the use of imaging Total Kidney Volume (TKV) as a prognostic biomarker that predicts the progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD) to select patients likely to respond to therapy into clinical trials. It aims to replace the currently used measurement of glomerular filtration rate (GFR). Scientists will use the data collected to develop a disease progression model that will evaluate the relationship between TKV and the known complications of ADPKD, including rate of loss of kidney function, hypertension, gross hematuria, kidney stones, urinary tract infections, development of end-stage renal disease, and mortality. These analyses will be used to support the regulatory qualification of TKV as an accepted measure for assessing the progression of ADPKD in clinical trials in which new therapies are tested. PKDOC has the following goals: # Develop standard clinical data elements and definitions that are specific to ADPKD # Create a database of aggregated data from existing multiple, longitudinal, and well-characterized research registries maintained over decades by the leading institutions in ADPKD clinical investigation # Advance and harmonize the missions of regulatory agencies by creating tools that help with the evaluation of new pharmaceutical compounds # Develop a quantitative disease progression model to examine the linkage between TKV and disease outcomes | consortium, drug, imaging, total kidney volume, biomarker, rate, disease progression, imaging biomarker, drug development, kidney volume, kidney, clinical, common data element, therapeutic, clinical trial, standard specification, database |
is listed by: Consortia-pedia has parent organization: Critical Path Institute; Arizona; USA |
PKD Foundation ; Philanthropic donations ; U.S. Food and Drug Administration |
nlx_157909 | SCR_003674 | PKD Outcomes Consortium, PKD Consortium, Polycystic Kidney Disease (PKD) Outcomes Consortium | 2026-02-16 09:46:12 | 0 | |||||||
|
AirPROM Resource Report Resource Website |
AirPROM (RRID:SCR_003827) | AirPROM | data or information resource, organization portal, consortium, portal | Consortium focused on developing computer and physical models of the airway system for patients with asthma and chronic obstructive pulmonary disease (COPD). Developing accurate models will better predict how asthma and COPD develop, since current methods can only assess the severity of disease. They aim to bridge the gaps in clinical management of airways-based disease by providing reliable models that predict disease progression and the response to treatment for each person with asthma or COPD. A data management platform provides a secure and sustainable infrastructure that semantically integrates the clinical, physiological, genetic, and experimental data produced with existing biomedical knowledge from allied consortia and public databases. This resource will be available for analysis and modeling, and will facilitate sharing, collaboration and publication within AirPROM and with the broader community. Currently the AirPROM knowledge portal is only accessible by AirPROM partners. | model, airway system, lung, consortium, clinical, imaging, respiratory system, tissue sample, airway model, genomic, gas diffusion mri, airway development, function, physiological, genetic, computational model, gene-environment interaction |
is listed by: Consortia-pedia has parent organization: European Lung Foundation |
European Union FP7 | nlx_158142 | SCR_003827 | Airway Disease Predicting Outcomes through Patient Specific Computational Modelling | 2026-02-16 09:46:15 | 0 | |||||||
|
BioSHaRE Resource Report Resource Website 10+ mentions |
BioSHaRE (RRID:SCR_003811) | BIOSHARE-EU | organization portal, narrative resource, consortium, portal, data or information resource, standard specification | A consortium of leading biobanks and international researchers from all domains of biobanking science to ensure the development of harmonized measures and standardized computing infrastructures enabling the effective pooling of data and key measures of life-style, social circumstances and environment, as well as critical sub-components of the phenotypes associated with common complex diseases. The overall aim is to build upon tools and methods available to achieve solutions for researchers to use pooled data from different cohort and biobank studies. This, in order to obtain the very large sample sizes needed to investigate current questions in multifactorial diseases, notably on gene-environment interactions. This aim will be achieved through the development of harmonization and standardization tools, implementation of these tools and demonstration of their applicability. BioSHaRE researchers are collaborating with P3G, the Global Alliance for Genomics and Health, IRDiRC (International Rare Diseases Research Consortium), H3Africa and other organizations on the development of an International Code of Conduct for Genomic and Health-Related Data Sharing. A draft version is available for external review. Generic documents have been prepared covering areas of biobanking that are of major importance. SOPs have been finalized for blood withdrawal (SOPWP5001blood withdrawal), manual blood processing (SOPWP5002blood processing), shipping of biosamples (SOPWP5003shipping) and withdrawal, processing and storage of urine samples (SOPWP5004urine). | gene-environment interaction, life-style, social circumstance, environment, phenotype, disease, biobank, socio-economic factor, data sharing, gene, clinical |
is listed by: Consortia-pedia has parent organization: University of Groningen; Groningen; Netherlands is parent organization of: BioResource Impact Factor |
European Union FP7 | nlx_158110 | SCR_003811 | Biobank Standardisation and Harmonisation for Research Excellence, Biobank Standardisation and Harmonisation for Research Excellence in the European Union | 2026-02-16 09:46:07 | 21 | |||||||
|
Canadian Consortium on Neurodegeneration in Aging Resource Report Resource Website |
Canadian Consortium on Neurodegeneration in Aging (RRID:SCR_003846) | CCNA | data or information resource, organization portal, consortium, portal | Consortium that will be the premier research hub for all aspects of research involving neurodegenerative diseases that affect cognition in aging - including Alzheimer's disease. They will promote high impact, inter-institutional and interdisciplinary collaboration through a pan-Canadian approach, and will position Canadian researchers to lead and participate in a new wave of national and international initiatives with congruent goals. The consortium focuses research into the basic mechanisms of neurodegenerative diseases, accelerating the development of tools that can be used to assist in the diagnosis and treatment of the diseases. The intended outcome of these tools is to improve the quality of life and services patients with neurodegenerative diseases. As part of the Canadian contribution to the International Collaborative Research Strategy for Alzheimer's disease, the consortium brings together Canadian government agencies (federal and provincial), foundations, pharmaceutical companies, philanthropists and international stakeholders to identify if there are common causes and risk factors to neurodegenerative diseases. The consortium is focused on three themes: * Primary Prevention aimed at preventing the disease from developing * Secondary Prevention focused on delaying the clinical manifestations of the already developing disease * Quality of Life designed for helping individuals, caregivers and the health system in the context of a clinically developed disease. | cognition, biomarker, primary prevention, secondary prevention, quality of life, clinical, late adult human, prevention |
is listed by: Consortia-pedia has parent organization: Institute of Aging - CIHR |
Canadian Institutes of Health Research ; Alzheimer Society of Canada ; Alzheimers Research UK |
nlx_158160 | SCR_003846 | Canadian Consortium on Neurodegeneration in Aging (CCNA) | 2026-02-16 09:46:16 | 0 | |||||||
|
MMRF CoMMpass Study Resource Report Resource Website |
MMRF CoMMpass Study (RRID:SCR_003721) | CoMMpass | organization portal, topical portal, consortium, portal, data or information resource, disease-related portal | A personalized medicine initiative to discover biomarkers that can better define the biological basis of multiple myeloma to help stratify patients. This effort hopes to obtain samples from approximately 1,000 multiple myeloma patients and follow them over time to identify how a patient's genetic profile is related to clinical progression and treatment response. As a partnership between 17 academic centers, 5 pharmaceuticals and the Department of Veterans Affairs, the goal of this eight year study is to create a database that can accelerate future clinical trials and personalized treatment strategies. MMRF's CoMMpass Study has the following goals: * Create a guide to which treatments work best for specific patient subgroups. * Share data with researchers to accelerate drug development for specific subtypes of multiple myeloma patients. In order to facilitate discoveries and development related to targeted therapies, the comprehensive data from CoMMpass is placed in an open-access research portal. The data will be part of the Multiple Myeloma Research Foundation's (MMRF) Personalized Medicine Platform combines CoMMpass data with those collected from MMRF's Genomics Initiative. It is hoped that the longitudinal data, combined with the annotated bio-specimens will help provide insights that can accelerate personalized therapies. | consortium, biomarker, molecular, genetic, blood, cancer, clinical, data sharing |
uses: Multiple Myeloma Genomics Portal is listed by: Consortia-pedia has parent organization: Multiple Myeloma Research Foundation |
United States Department of Veterans Affairs ; Multiple Myeloma Research Foundation |
nlx_157899 | SCR_003721 | Relating Clinical Outcomes in MM to Personal Assessment of Genetic Profile, Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Study, Multiple Myeloma Research Foundation (MMRF) - CoMMpass Study | 2026-02-16 09:46:14 | 0 | |||||||
|
BiomarCaRE Resource Report Resource Website 10+ mentions |
BiomarCaRE (RRID:SCR_003841) | BIOMARCARE, BiomarCaRE | data or information resource, organization portal, consortium, portal | EU funded consortium including over 30 partner from academia and industry. BiomarCaRE aims to determine the value of established and emerging biomarkers to improve risk estimation of cardiovascular disease in Europe. BiomarCaRE relies on an exceptional resource of large scale epidemiological cohorts with long term follow-up and available bio specimens based on the population of the MORGAM Project as well as several cardiovascular disease cohorts and clinical trials. | drug, biomarker, diagnostic, cardiovascular risk, phenotype, ultrasound, mri, clinical, epidemiological, risk prediction, lifestyle, risk factor, heart | is listed by: Consortia-pedia | European Union FP7 | nlx_158154, SCR_013677 | SCR_003841 | BiomarCaRE.EU, Biomarker for Cardiovascular Risk Assessment in Europe (BIOMARCARE), Biomarker for Cardiovascular Risk Assessment in Europe | 2026-02-16 09:46:16 | 27 | |||||||
|
Nephrology Nursing Certification Commission Resource Report Resource Website |
Nephrology Nursing Certification Commission (RRID:SCR_003994) | NNCC | data or information resource, training resource, organization portal, portal | Organization that established credentialing mechanisms to promote patient safety and to improve the quality of care provided to nephrology patients. There is a diversity of examinations providing the opportunity for certification at various levels of education, experience, and areas of practice within nephrology nursing. All of the certification examinations are endorsed by American Nephrology Nurses'''' Association (ANNA). The Commission recognizes the value of education, administration, research, and clinical practice in fostering personal and professional growth and currently provides six examinations to validate clinical performance: * The Certified Dialysis Nurse examination * The Certified Dialysis LPN/LVN examination * The Certified Nephrology Nurse examination * The Certified Clinical Hemodialysis Technician * The Certified Clinical Hemodialysis Technician - Advanced * The Certified Nephrology Nurse - Nurse Practitioner | nephrology, kidney, nursing, certification, clinical, dialysis, hemodialysis |
is related to: American Nephrology Nurses Association is related to: Kidney Health Initiative |
Kidney disease | nlx_158407 | SCR_003994 | Nephrology Nursing Certification Board, NNCB | 2026-02-16 09:46:18 | 0 | |||||||
|
EGAPP Resource Report Resource Website 1+ mentions |
EGAPP (RRID:SCR_004189) | EGAPP | data or information resource, topical portal, portal | Initiative to develop a systematic, evidence-based process for evaluating genetic tests and other applications of genomic technology that are rapidly moving from research to use in clinical practice. A key objective of this process is to provide objective, timely, and credible information that is clearly linked to the scientific evidence on specific applications of genetic and genomic tests. The primary focus of EGAPP activities is an independent, nonfederal expert panel, the EGAPP Working Group. Other components of the EGAPP initiative include a federal interagency, the CDC staff and consultants, and an EGAPP initiative evaluation team. | genetic test, genomics, clinical, genomic technology, evaluation, public health |
is listed by: OMICtools has parent organization: Centers for Disease Control and Prevention |
OMICS_01538 | SCR_004189 | Evaluation of Genomic Applications in Practice and Prevention (EGAPP), Evaluation of Genomic Applications in Practice and Prevention | 2026-02-16 09:46:17 | 1 | ||||||||
|
Wellcome Images Resource Report Resource Website |
Wellcome Images (RRID:SCR_004181) | Wellcome Images | image repository, image collection, data repository, database, storage service resource, service resource, data or information resource | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 9, 2023.Digital collection of images, with themes ranging from medical and social history to contemporary healthcare and biomedical science. The collection contains historical images from the Wellcome Library collections, Tibetan Buddhist paintings, ancient Sanskrit manuscripts written on palm leaves, beautifully illuminated Persian books and much more. The Biomedical Collection holds over 40 000 high-quality images from the clinical and biomedical sciences. Selected from the UK''s leading teaching hospitals and research institutions, it covers disease, surgery, general healthcare, sciences from genetics to neuroscience including the full range of imaging techniques. They are always looking for new high quality biomedical images from scientific researchers, clinical photographers and artists in any field of science or medicine. As a contributor you retain your original material and copyright, and receive commission and full credit each time your images are used. The annual Wellcome Images awards (previously known as Biomedical Images Awards) reward contributors for their outstanding work and winners are chosen by a panel of experts. The resulting public exhibitions are always extremely popular and receive widespread acclaim. All images on the Wellcome Images site are available free for use in: * private study and non-commercial research * examination papers * criticism and review, this applies only where there are no multiple copies made * theses submitted by a student at a higher or further education institution for the purposes of securing a degree * personal use by private individuals | biomedical, clinical, disease, surgery, healthcare, genetics, neuroscience, imaging, science, medicine, history, painting, manuscript | Wellcome Trust | THIS RESOURCE IS NO LONGER IN SERVICE | r3d100010779, nlx_143611 | https://doi.org/10.17616/R3HS58 | SCR_004181 | 2026-02-16 09:46:20 | 0 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the NIF Resources search. From here you can search through a compilation of resources used by NIF and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that NIF has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on NIF then you can log in from here to get additional features in NIF such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into NIF you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
Welcome to the Neuroscience Information Framework Project, designed to serve the biomedical research community. NIF maintains the largest searchable collection of neuroscience data, the largest catalog of biomedical resources, and the largest ontology for neuroscience on the web. We welcome all feedback and suggestions and are actively looking for resource providers to make their resources accessible through NIF. Learn about the tools available to help you share your data and discover a dynamic inventory of Web-based neuroscience resources.
